Endpoints News Unveils 2026 Top 11 Biotech Startups Amid Industry Shifts

Key points

• Endpoints News selected 11 startups from more than 150 nominations, including Anew Labs, Kali Therapeutics, and SonoThera.
• The 2026 honorees were announced at a gala in Boston on September 24, 2026, with a replay available on September 28.
• Kali Therapeutics, founded in 2024, was recognized for its rapid execution, including a $180 million upfront deal with Sanofi.
• The list reflects a biotech industry that has regained funding but faces shifting power structures involving AI and China.
• Categories covered include gene therapy, CAR-T, cardiology, longevity, and robotics.

Background

The Endpoints 11 awards are an annual tradition by Endpoints News, part of the Financial Times' FT Specialist group, to identify the most promising private biotechnology companies. Previous years have highlighted various emerging trends in the sector, but the 2026 list specifically addresses the current state of the industry as described by the primary source.

How outlets are covering it

Endpoints News emphasizes the return of funding to public and private markets, driven by fundamentals rather than pandemic-era narratives, while also noting increased uncertainty due to rising influence from AI and China. Kali Therapeutics, via PR Newswire, highlights its rapid progress, including FDA clearance for KT501 and a partnership with Sanofi, framing the award as recognition for scientific risk and execution speed. The Manila Times provided limited coverage, focusing solely on K2 Therapeutics as an honoree. Yahoo Finance's coverage was largely obscured by technical errors and market data, offering no substantive perspective on the awards themselves.

Why it matters

The Endpoints 11 list serves as a barometer for the direction of the biotech industry, highlighting shifts in power structures and the emergence of new players. The inclusion of companies like Anew Labs (a China-based AI rival) and Kali Therapeutics (with a major Sanofi deal) indicates the growing importance of AI and international partnerships in biotech. The list also underscores the industry's recovery from previous uncertainties, with funding returning to markets, while also signaling new challenges and opportunities in areas like gene therapy and longevity.

What to watch

Endpoints News will provide a replay of the Boston gala on September 28, 2026, where the selection process and rationale for the 2026 honorees will be discussed. The company will closely monitor the progress of the 11 startups, noting that while some may achieve deals, IPOs, or drug approvals, others may fail. Kali Therapeutics plans to continue advancing its pipeline, including KT502 and KT209, with first-in-human studies for KT209 planned for the first half of 2027.